the ipledge program rems (risk evaluation and mitigation strategy) the ipledge program rems is a safety program to manage the risk of isotretinoin’s teratogenicity and to minimize fetal exposure. the rems is required by the u.s. food and drug administration (fda) to ensure the benefits of isotretinoin outweigh its risks.

we’re solving patient problems in a way where everyone wins. learn more about covermymeds.

an award-winning diagnostic clinical decision support system that enhances diagnostic accuracy, aids therapeutic decisions, and improves patient safety.

welcome to dermnet, the world's leading free dermatology resource. scroll through evidence-based information on dermatological diseases (skin conditions), procedures, and treatments.

solutions to help life sciences organizations drive healthcare forward and get the right treatments to patients, faster.

labcorp helps patients, providers, organizations, and biopharma companies to guide vital healthcare decisions each and every day.

wolters kluwer is a global provider of professional information, software solutions, and services.

the fda is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that products that emit radiation.

medfar clinical solutions offers myle, a web-based, cloud-hosted emr solution for doctors and private physician clinics.

providing accurate, impartial information on more than 24,000 prescription drugs and otc medications.